Literature DB >> 18353141

How to make a melanoma: what do we know of the primary clonal events?

Dorothy C Bennett1.   

Abstract

Rapid advances have been made in our knowledge of the commonest genetic and epigenetic alterations found in human sporadic melanomas. Valuable recent contributions came from analyses of gene copy number by comparative genome hybridization, and from large-scale gene expression profiling. All of the commonest affected genes encode regulatory components. Loci with established importance in melanoma, like CDKN2A, BRAF and PTEN, have been joined by some less familiar genes including transcription factor sequences TBX2 and STK11 (LKB). This knowledge is reviewed in relation to the cellular signaling pathways affected by these molecules, their biological outcomes, and the implications as to what changes are required overall to generate a melanoma. The data support a model in which genesis of melanoma requires changes that (1) initiate clonal expansion, (2) overcome cell senescence, and (3) reduce apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353141     DOI: 10.1111/j.1755-148X.2007.00433.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  69 in total

1.  Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?

Authors:  Sara Di Lorenzo; Daniele Fanale; Bartolo Corradino; Valentina Caló; Gaetana Rinaldi; Viviana Bazan; Antonio Giordano; Adriana Cordova; Antonio Russo
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

2.  Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  S Martín-Algarra; M T Fernández-Figueras; J A López-Martín; A Santos-Briz; A Arance; M D Lozano; A Berrocal; J J Ríos-Martín; E Espinosa; J L Rodríguez-Peralto
Journal:  Clin Transl Oncol       Date:  2013-10-16       Impact factor: 3.405

3.  Novel targeted therapies for the treatment of metastatic melanoma.

Authors:  Ragini Kudchadkar
Journal:  Ochsner J       Date:  2010

4.  Toward predicting metastatic progression of melanoma based on gene expression data.

Authors:  Yuanyuan Li; Juno M Krahn; Gordon P Flake; David M Umbach; Leping Li
Journal:  Pigment Cell Melanoma Res       Date:  2015-04-24       Impact factor: 4.693

Review 5.  CDK4 inhibitors an emerging strategy for the treatment of melanoma.

Authors:  Belinda Lee; Grant A McArthur
Journal:  Melanoma Manag       Date:  2015-08-10

Review 6.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

7.  Wnt signaling potentiates nevogenesis.

Authors:  Jeff S Pawlikowski; Tony McBryan; John van Tuyn; Mark E Drotar; Rachael N Hewitt; Andrea B Maier; Ayala King; Karen Blyth; Hong Wu; Peter D Adams
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

8.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

9.  A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.

Authors:  Janice M Mehnert; Ann W Silk; J H Lee; Liesel Dudek; Byeong-Seon Jeong; Jiadong Li; Jason M Schenkel; Evita Sadimin; Michael Kane; Hongxia Lin; Weichung J Shih; Andrew Zloza; Suzie Chen; James S Goydos
Journal:  Pigment Cell Melanoma Res       Date:  2018-04-10       Impact factor: 4.693

Review 10.  Small molecules and targeted therapies in distant metastatic disease.

Authors:  P Hersey; L Bastholt; V Chiarion-Sileni; G Cinat; R Dummer; A M M Eggermont; E Espinosa; A Hauschild; I Quirt; C Robert; D Schadendorf
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.